Tango Therapeutics Strengthens Leadership Team To Support Advancement And Potential Approval Of Vopimetostat In Pancreatic Cancer

Tango Therapeutics, Inc., a clinical-stage biotechnology company focused on developing the next generation of precision cancer medicines, announced several key leadership appointments to support the rapid advancement of vopimetostat, its highly potent and selective PRMT5 inhibitor. The company is preparing for the potential first regulatory approval of vopimetostat in pancreatic cancer and has added three experienced industry leaders to strengthen its capabilities. Matthew Gall has been appointed Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer, and Janice Kapty, PhD, as SVP of Corporate Strategy and Project Leadership.

Malte Peters, MD, President and Chief Executive Officer of the company, explained that Tango’s recent clinical progress and its strong scientific foundation position vopimetostat as a potentially important treatment for patients with pancreatic and other cancers. To support the company’s growth and prepare for late-stage development and possible commercialization, the leadership team is being expanded across finance, development operations and strategic planning. Dr. Peters also expressed appreciation for the contributions of the company’s former Chief Financial Officer, Daniella Beckman, who played a major role in taking the company public and leading multiple successful financings.

Matthew Gall assumes the role of Chief Financial Officer beginning April 15, succeeding Daniella Beckman. He brings extensive experience in biotechnology finance, corporate development and strategic transactions. His prior roles include Chief Financial Officer at both Kalaris Therapeutics and iTeos Therapeutics, along with senior finance and business development positions at Sarepta Therapeutics, Celgene Corporation and Gilead Sciences.

Yen-Ching Chua joins the company as Chief Development Operations Officer effective June 1. She will oversee clinical operations, including data management, clinical compliance, quality and clinical sourcing. Her background includes leading global development and clinical operations across complex oncology portfolios at Novocure, Debiopharm International, MorphoSys and Novartis, giving her substantial experience managing multinational development programs.

Janice Kapty, PhD, has been appointed SVP of Corporate Strategy and Project Leadership, effective April 15. In this role, she will oversee portfolio strategy, lead the project management organization, and provide strategic project leadership for vopimetostat as well as other therapies in the pipeline, including TNG456. Dr. Kapty has previously guided drug development programs at Arvinas, MorphoSys, Constellation Pharmaceuticals, Bristol Myers Squibb and Celgene Corporation.

These appointments reinforce the company’s commitment to advancing vopimetostat and its broader pipeline. By strengthening expertise across finance, operations and strategic planning, Tango Therapeutics, Inc. is positioning itself for continued progress in late-stage development, future data readouts and potential commercialization efforts.